To explore the effect of USP22 on current melanoma treatment and cell death inducers, we screened the vulnerability of USP22‐deficient melanoma cells to a series of antimelanoma drugs, including BRAF/MEK inhibitors, NHWD‐870 (a novel oral BET inhibitor developed by our team),38, 39, 40 and cell death inducers, such as inducers of apoptosis (staurosporine), necroptosis (HS‐173), ferroptosis (RSL3), and cuproptosis (elesclomol‐Cu) (Figures 7A and S7A). Here, MAP2K7 is linked to melanoma.